{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:14:30Z","timestamp":1789470870509,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01498","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T05:19:06Z","timestamp":1595913546000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["FVIII Immunogenicity\u2014Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A"],"prefix":"10.3389","volume":"11","author":[{"given":"Daniel P.","family":"Hart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"B1","article-title":"Official Journal of the European Union (2009) 2009\/C 151\/02 Report From the Commission to the European Parliament, The Council, The European Economic and Social Committee and the Committee of the Regions","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/002224297003400125","article-title":"Our experience in Sweden with prophylaxis on hemophilia","volume":"34","author":"Nilsson","year":"1970","journal-title":"Bibl Haematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost."},{"key":"B4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/203312a0","article-title":"High-potency antihaemophilic factor concentrate prepared from cryoglubulin precipitate","volume":"203","author":"Pool","year":"1964","journal-title":"Nature."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJM196512302732701","article-title":"Production of high-potency concentrates of antihemophilic globulin in a closed-bag system","volume":"273","author":"Pool","year":"1965","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJM198901193200307","article-title":"Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia","volume":"320","author":"White","year":"1989","journal-title":"N Engl J Med."},{"key":"B7","first-page":"340","article-title":"The mode of action and aetiology of antihaemophilic globulin inhibitors","volume":"30","author":"Biggs","year":"1959","journal-title":"Sang."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1182\/blood-2014-07-580498","article-title":"Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000\u20132011","volume":"124","author":"Collins","year":"2014","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1111\/j.1538-7836.2006.02127.x","article-title":"The international immune tolerance study: a multicenter prospective randomized trial in progress","volume":"4","author":"Dimichele","year":"2006","journal-title":"J Thromb Haemost."},{"key":"B10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/hae.12621","article-title":"Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs prophylaxis and on-demand with bypass treatment","volume":"21","author":"Earnshaw","year":"2015","journal-title":"Hemophilia."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products inhibitor development in severe hemophilia A.","volume":"368","author":"Gouw","year":"2013","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1055\/s-0038-1649954","article-title":"Hemophilia A: mutation type determines risk of inhibitor formation","volume":"74","author":"Schwaab","year":"1995","journal-title":"Thromb Haemost."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2006-05-024711","article-title":"Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A","volume":"108","author":"Astermark","year":"2006","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J Thromb Haemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1182\/blood-2012-06-434803","article-title":"The polygenic nature of inhibitors in hemophilia A: results from the hemophilia inhibitor genetics study (HIGS) combined cohort","volume":"121","author":"Astermark","year":"2013","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1055\/s-0038-1655945","article-title":"HLA genotype of patients with severe hemophilia A due to intron 22 inversion with and without inhibitors of factor VIII","volume":"77","author":"Oldenburg","year":"1997","journal-title":"Thromb Haemost."},{"key":"B19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1365-2141.1990.tb07878.x","article-title":"Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies","volume":"76","author":"Aly","year":"1990","journal-title":"Br J Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1055\/s-0038-1655944","article-title":"HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party","volume":"77","author":"Hay","year":"1997","journal-title":"Thromb Haemost."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"Eckhardt","year":"2013","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1160\/TH14-11-0940","article-title":"Inhibitors in nonsevere hemophilia A: outcome and eradication strategies","volume":"114","author":"van Velzen","year":"2015","journal-title":"Thromb Haemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bjh.14543","article-title":"Treatment burden, haemostatic strategies real world inhibitor screening practice in non-severe hemophilia A","volume":"176","author":"Batty","year":"2017","journal-title":"Br J Haematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood-2002-05-1369","article-title":"CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild\/moderate hemophilia A","volume":"101","author":"Jacquemin","year":"2003","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1538-7836.2011.04202.x","article-title":"T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site","volume":"9","author":"James","year":"2011","journal-title":"J Thromb Haemost."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1182\/blood-2009-01-200725","article-title":"Lineages of human T-cell clones, including T helper 17\/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses","volume":"114","author":"Ettinger","year":"2009","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1538-7836.2009.03357.x","article-title":"Intensive peri-operative use of factor VIII and the Arg593\u2013>Cys mutation are risk factors for inhibitor development in mild\/moderate hemophilia A","volume":"7","author":"Eckhardt","year":"2009","journal-title":"J Thromb Haemost."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/jth.12990","article-title":"Inhibitor development mortality in non-severe hemophilia A","volume":"13","author":"Eckhardt","year":"2015","journal-title":"J Thromb Haemost."},{"key":"B29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bjh.13131","article-title":"A large-scale computational study of inhibitor risk in non-severe hemophilia A","volume":"168","author":"Shepherd","year":"2015","journal-title":"Br J Haematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/1471-2105-10-296","article-title":"NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction","volume":"10","author":"Nielsen","year":"2009","journal-title":"BMC Bioinform."},{"key":"B31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3324\/haematol.2018.195669","article-title":"Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A","volume":"104","author":"Hart","year":"2019","journal-title":"Haematologica."},{"key":"B32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/hae.12276","article-title":"In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in hemophilia A patients with missense mutations in the F8 gene","volume":"20","author":"Pashov","year":"2014","journal-title":"Haemophilia."},{"key":"B33","doi-asserted-by":"publisher","first-page":"12862","DOI":"10.1111\/ijlh.12862","article-title":"Optimization of pre-analytical heat treatment for inhibitor detection in hemophilia A","volume":"40","author":"Batty","year":"2018","journal-title":"Int J Lab Hematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1182\/bloodadvances.2018019323","article-title":"HLA-DRB1-factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study","volume":"2","author":"Kempton","year":"2018","journal-title":"Blood Adv."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0206654","DOI":"10.1371\/journal.pone.0206654","article-title":"Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition","volume":"13","author":"Schneidman-Duhovny","year":"2018","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/nm.2248","article-title":"A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes","volume":"16","author":"Hartman","year":"2010","journal-title":"Nat Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/nmeth.2182","article-title":"Global identification of peptidase specificity by multiplex substrate profiling","volume":"9","author":"O'Donoghue","year":"2012","journal-title":"Nat Methods."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1093\/bioinformatics\/btt560","article-title":"Optimized atomic statistical potentials: assessment of protein interfaces and loops","volume":"29","author":"Dong","year":"2013","journal-title":"Bioinformatics."},{"key":"B39","doi-asserted-by":"publisher","first-page":"M110","DOI":"10.1074\/mcp.M110.002246","article-title":"HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII","volume":"10","author":"van Haren","year":"2011","journal-title":"Mol Cell Proteomics."},{"key":"B40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3324\/haematol.2017.175083","article-title":"Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides presented by monocyte-derived dendritic cells","volume":"103","author":"Peyron","year":"2018","journal-title":"Haematologica."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T05:19:09Z","timestamp":1595913549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2020.01498"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01498","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"article-number":"1498"}}